Insider sale and related grants
Melina Cioffi, who serves as Senior Vice President for Regulatory Affairs at Aquestive Therapeutics, Inc. (NASDAQ: AQST), disposed of 25,311 common shares on March 10, 2026, for an aggregate amount of approximately $105,622. The shares sold at transaction prices that ranged from $4.17 to $4.32 per share, transactions that sit close to the quoted stock price of $4.27 at the time the reporting was prepared.
Concurrent Form 4 disclosures
The related Form 4 filing with the Securities and Exchange Commission shows Cioffi acquired 100,000 shares of common stock on March 9, 2026, with an indicated value of $0. The filing also records a grant of 75,000 Non-Qualified Stock Options with an exercise price set at $4.29 and an expiration date of 2036-03-09. After completing the sale on March 10, Cioffi is reported to directly own 274,867 shares of Aquestive Therapeutics.
Market context and valuation note
The timing of the sale emerges against mixed recent market performance for AQST. The stock has risen about 62% over the past 12 months, though it has fallen 34% year-to-date. An InvestingPro analysis referenced in the filing materials indicates the stock currently appears overvalued relative to its Fair Value.
Recent financial results and analyst view
Aquestive released its fourth-quarter 2025 results showing a wider-than-expected per-share loss. The company reported a net loss of $0.26 per share for the quarter, missing analyst expectations that had forecast a $0.13 loss per share. Quarterly revenue was reported at $13 million, slightly below the consensus estimate of $13.34 million.
Separately, Citizens reiterated a Market Outperform rating for Aquestive and maintained a $10.00 price target. The firm stated that the pathway to an NDA re-submission for Anaphylm appears clear and noted an upcoming FDA meeting is expected to clarify remaining steps. Aquestive has reiterated its own timeline for resubmitting the Anaphylm NDA in the third quarter of 2026.
Where to find further analysis
For investors seeking a more detailed view of AQST’s valuation and related analysis, a Pro Research Report is available on InvestingPro.
Key points
- Melina Cioffi sold 25,311 shares on March 10, 2026, for approximately $105,622, at prices between $4.17 and $4.32.
- The Form 4 shows Cioffi received 100,000 shares valued at $0 on March 9, 2026, and 75,000 Non-Qualified Stock Options exercisable at $4.29 expiring 2036-03-09.
- Aquestive reported Q4 2025 results with a $0.26 per-share loss and $13 million in revenue; Citizens reiterates Market Outperform with a $10.00 target and cites clarity on the Anaphylm re-submission path.
Risks and uncertainties
- Near-term stock volatility - AQST has fallen 34% year-to-date despite a 62% 12-month gain, indicating potential market volatility affecting equity investors.
- Regulatory and resubmission timing - The Anaphylm NDA re-submission is planned for the third quarter of 2026, but regulatory steps and the upcoming FDA meeting introduce uncertainty for the company’s strategic timeline.
- Operational and financial performance - Q4 2025 results missed analyst expectations on both earnings and revenue, which could continue to pressure market sentiment and access to capital.